Acute Myeloid Leukemia (AML) – Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040

Acute Myeloid Leukemia (AML) Epidemiology Insights

Thelansis’s “Acute Myeloid Leukemia (AML) Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

⁠Acute Myeloid Leukemia (AML) Overview

Acute Myeloid Leukemia (AML) is an aggressive clonal hematopoietic malignancy arising from myeloid progenitor cells, characterized by the rapid accumulation of immature blast cells in the bone marrow. Somatic mutations in FLT3, NPM1, IDH1, IDH2, and TP53 alongside cytogenetic aberrations guide European LeukemiaNet risk stratification and subsequent treatment intensity. Intensive induction chemotherapy remains the frontline standard for fit patients, followed by allogeneic stem cell transplantation for intermediate and adverse risk profiles, while venetoclax combined with hypomethylating agents serves as the care standard for unfit cohorts. Targeted options have fundamentally transformed molecular sub-segments. Frontline maintenance features FLT3 inhibitors like midostaurin or quizartinib alongside targeted IDH inhibitors (ivosidenib, enasidenib). Crucially, the relapsed or refractory setting has transitioned with the formal approvals of oral menin inhibitors. This targeted class includes Revuforj (revumenib) indicated for KMT2A-rearranged and NPM1-mutated presentations, alongside the once-daily agent Komzifti (ziftomenib) for refractory NPM1-mutated cohorts. Both menin inhibitors require strict monitoring for class-specific differentiation syndrome. Multidisciplinary care and rigid measurable residual disease (MRD) tracking are essential to optimize long-term survival.

Market Definition:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Deliverables format and updates*:

  • Access to an interactive epidemiology platform with downloadable Excel and PPT files.
    • Global findings
    • G8 findings
    • Regional findings
    • Country-specific findings
  • Others*: regular updates, customizations, epidemiologist support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

  • 20-year historical and forecast data (2020–2040)
  • Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
  • Granular patient population coverage by year and geography
  • Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
  • Patient funnels
  • Country comparisons
  • Relevant clinical variables (e.g., staging/classification/severity)

Insights driven by robust research and estimates:

  • Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
  • Primary market research with KOLs
  • RWD analysis using claims and EHR datasets
  • Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)

Read more: Acute Myeloid Leukemia (AML) – Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more